Tight Control of Growth Hormone: An Attainable Outcome for Acromegaly Treatment

Shlomo Melmed, M.D.

Cedars-Sinai Research Institute Los Angeles, California 90048

Address correspondence and requests for reprints to: Shlomo Melmed, M.D., Academic Affairs, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048. E-mail: melmed{at}csmc.edu


    Introduction
 Top
 Introduction
 References
 

Acromegaly, an insidious neuroendocrine disorder, leads to debilitating acral and metabolic disturbances (1). The disease has long been recognized to be associated with enhanced mortality due to cardiovascular, pulmonary, and neoplastic disease (2, 3, 4, 5, 6). Enhanced surgical microtechniques, improved stereotactic radiation, and the advent of potent peptide analog therapy to effectively inhibit pituitary adenoma GH hypersecretion (7), together with development of ultrasensitive GH assays (8, 9), have allowed a more stringent biochemical remission to be both defined and attained. Accordingly, sensitive imaging, biochemical and epidemiologic techniques have been applied to more accurately determine therapeutic outcomes in acromegaly.

Successful therapy of acromegaly should normalize GH and insulin-like growth factor I (IGF-I) secretion, ablate or contain the adenoma mass and its local pressure effects, improve systemic morbidity, and ultimately, normalize mortality (7). In this issue of JCEM, two comprehensive papers address the important question of long-term acromegaly treatment outcomes (see pages 3411 and 3419) (10, 11). Remarkably, the initial results of surgical resection of GH-secreting adenomas, as reported by these two highly experienced neurosurgical groups are quite similar. Abosch et al. (10) report short-term remission (GH < 5 µg/L) in 76% of 254 patients, with the majority of 129 ascertainable patients remaining in long-term remission. Clearly, the biochemical parameter of "basal" GH less than 5 µg/L does not reflect normalization of GH hypersecretion, as GH secretion is normally pulsatile, with peaks often reaching 20 µg/L or more. Nevertheless, the impressive finding of this study is that, even using this less stringent criterion of remission, the mortality rate achieved was equivalent to that in matched controls, in contrast to the 2.4–4.8-fold enhanced mortality in those patients with persistent disease. However, many of their patients appeared to harbor microadenomas, as assessed by older insensitive and imprecise imaging techniques, and thus, extrapolation of earlier observations may not reflect current experience with improved magnetic resonance imaging, sensitive GH assays, and sophisticated biochemical follow-up. In their study, Swearingen et al. (11), using more stringent criteria for remission (normalized IGF-I levels or GH suppression to <2 µg/L after glucose loading), report that over 90% of patients harboring microadenomas successfully achieved these criteria. Significantly, however, less than 50% of patients harboring macroadenomas were biochemically controlled. Unfortunately, the majority of patients in their series (129/162) harbored macroadenomas, similar to reported experience in most other studies (1). Importantly, the mortality risk in 86 patients cured at surgery did not differ from controls, while in those patients with persistent disease, even after adjuvant radiation or medical therapy, mortality remained significantly increased (almost 2-fold). Thus, both these studies confirm two earlier less comprehensive reports suggesting that the level of attained GH is the single most important determinant of mortality in acromegaly (5, 6). Regardless of treatment mode, therefore, normalization of GH levels appears to restore mortality risk to that of age-matched population controls. Conversely, disease persistence postoperatively is associated with a 3.5-fold relative mortality risk.

In both these series, postoperative complications occurred in approximately 5–8% of patients. These surgically related adverse events included permanent diabetes insipidus, cerebrospinal fluid leaks requiring repair, meningitis, severe sinusitus, and hypopituitarism. Thus, significant perioperative morbidity remains of concern, especially for patients operated on by less experienced surgeons. Two adjuvant modes of therapy, irradiation and somatotropin release- inhibiting factor (SRIF) analogs, also have their respective disadvantages, including development of pituitary failure in most irradiated patients, local central nervous system damage in a small number of patients, and asymptomatic gallstones in up to 30% of patients receiving SRIF analogs.

The challenge of tight GH control can now be met with greater stringency. Pituitary radiation may be administered but usually requires up to 12 yr or more for suppression of GH levels to less than 5 µg/L (12). Recently, the relative failure of irradiation to effectively normalize IGF-I levels in the long-term has also been documented, implying persistent albeit low levels of GH hypersecretion in these patients (13). Novel radiosurgical techniques, including stereotactic technology and use of the gamma knife, now offer focused tumor ablation, although long-term safety and efficacy are not yet known.

Long-acting somatostatin analogs (14) are effective and safe in managing GH hypersecretion and the resultant systemic effects of acromegaly in patients in whom surgical resection has failed to achieve a stringent biochemical remission. SRIF analogs are also of use in those patients who have undergone irradiation and in whom GH levels may remain unacceptably elevated for up to 15 yr (15). Somatostatin analogs may also be offered as primary therapy, especially in those patients who refuse surgery or have other medical risk factors (7). As now confirmed in this issue (10, 11), most patients harboring macroadenomas have persistent postsurgical GH hypersecretion, and use of SRIF analogs should be weighed against radiotherapy for these patients. Long-acting injectable depot analogs administered once every 14–30 days enhance patient convenience and compliance while retaining drug sensitivity (16, 17). Novel somatostatin receptor-subtype selective analogs (18) and GH-receptor antagonists (19), the current investigational tools, hold promise for improved efficacy and patient benefit. Interestingly, prior surgery appears not to alter the long-term efficacy of somatostatin analogs (20), thus raising the question of the need for surgery if no tumor mass effects are present. However, drug cost and patient compliance need to be factored in to the therapeutic decision-making. Nevertheless, well-controlled prospective comparisons of surgery versus primary SRIF analog therapy are required to adequately address the respective roles of each modality.

Several challenges remain in determining optimal therapy for acromegaly. Clearly, the availability of robust and reproducible GH and IGF-I assays are sorely needed. Age- and sex-matched control information for these commercially available assays are not optimal, and a clearer biochemical definition of the normal adult GH-IGF-I axis is required (8, 9). Larger tumors remain poor surgical risks, and earlier diagnosis would be beneficial. Nevertheless, increasing physician awareness will be difficult as the onset of this rare disease is insidious; often, up to a mean of 12 yr elapses from time of symptom onset to establishment of the diagnosis (1). The challenge facing the endocrinologist is to refer our patients to highly experienced, competent surgeons. As pointed out in both studies, world-wide reported surgical results (21) with few exceptions (22, 23) are not acceptable. Unfortunately, the unpublished experience is of more concern, and as practicing endocrinologists we should insist on the best surgical referrals for our patients.

The clinical consequences of unrestrained GH-IGF-I secretion should clearly be addressed in an integrated management strategy for acromegaly. Aggressive management of cardiovascular disease and hypertension, pulmonary function improvement, sleep apnea assessment and treatment, colonoscopy screening, diabetes care, and rheumatologic assessment and therapy should be coordinated. Patient-focused issues including maxillofacial dysfunction, fertility, and self-image concerns should also be addressed as integral components of the comprehensive management of acromegaly.

As exemplified in the two reports (10, 11), multimodal therapy now allows the goal of tight GH control and normalized mortality to be realistic and readily attainable for the majority of patients with acromegaly. Hopefully, this aggressive approach will prevent onset and/or progression of the debilitating features of acromegaly.

Received August 12, 1998.

Accepted August 12, 1998.


    References
 Top
 Introduction
 References
 

  1. Melmed S. 1990 Acromegaly. N Engl J Med. 322:966–977.[Medline]
  2. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. 1980 Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 12:71–79.[Medline]
  3. Bengtsson BA, Eden S, Ernest I, Oden A, Sjögren B. 1988 Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 223:327–335.[Medline]
  4. Wright AD, Hill DM, Lowy C, Fraser TR. 1970 Mortality in acromegaly. Q J Med. 34:1–16.
  5. Bates AS, Van’t Hoff W, Jones JM, Clayton RN. 1993 An audit of outcome of treatment in acromegaly. Q J Med. 86:293–299.[Medline]
  6. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol. 41:95–102.[Medline]
  7. Melmed S, Jackson I, Kleinberg D, Klibanski A. 1998 Current treatment guidelines for acromegaly. J Clin Endocrinol Metab. 83:2646–2652.[Abstract/Free Full Text]
  8. Chapman IM, Hartmann ML, Straue M, Johnson ML, Veldhuis JD, Thorner MO. 1994 Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab. 78:1312–1317.[Abstract]
  9. Iranmanesh A, Grisso B, Veldhuis JD. 1994 Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab. 78:526–535.[Abstract]
  10. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. 1998 Transephenoidal microsurgery for growth-hormone secreting pituitary adenomas: Initial outcome and long-term results. J Clin Endocrinol & Metab. 83:3411–3418.[Abstract/Free Full Text]
  11. Swearingen B, Barker II FG, Katznelson L, et al. 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol & Metab. 83:3419–3426.[Abstract/Free Full Text]
  12. Eastman RC, Gorden P, Glatstein E, Roth J. 1992 Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 21:693–712.[Medline]
  13. Barkan AL, Halasz I, Dornfeld KJ, et al. 1997 Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 82:3187–3191.[Abstract/Free Full Text]
  14. Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E. 1985 The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab. 60:1161–1165.[Abstract]
  15. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. 1995 Depot long-acting somatostatin analog (Sandostatin-LAR) is effective treatment for acromegaly. J Clin Endocrinol Metab. 80:3267–3272.[Abstract]
  16. Newman B, Melmed S, Snyder PJ, et al. 1995 Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients—a clinical research center study. J Clin Endocrinol Metab. 80:2768–2775.[Abstract]
  17. Caron P, Morange-Ramos I, Cogne M, Jaquet P. 1997 Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 82:18–22.[Abstract/Free Full Text]
  18. Shimon I, Yan X, Taylor J, Weiss MH, Culler MD, Melmed S. 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas: novel potential therapy for functional pituitary tumors. J Clin Invest. 100:2386–2392.[Abstract/Free Full Text]
  19. Chen WY, Chen N, Yun J, Wagner TE, Kopchick JJ. 1994 In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem. 269:15892–15897.[Abstract/Free Full Text]
  20. Newman C, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol & Metab. In press.
  21. Ross DA, Wilson CB. 1988 Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg. 68:854–867.[Medline]
  22. Fahlbusch R, Honogger J, Schott W, Buchfelder M. 1994 Results of surgery in acromegaly. In: Wass JAH, ed. Treating acromegaly. Bristol, UK: Journal of Endocrinology Ltd; 49–54.
  23. Laws Jr ER, Carpenter SM, Scheithauer BW, Randall RV. 1987 Long-term results of transsphenoidal surgery for the management of acromegaly. In: Robbins R, Melmed S, eds. Acromegaly: a century of scientific and clinical progress. New York: Plenum Press; 241–248.